跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ISRCTN59395590
ISRCTN59395590已完成1 期

A Phase I/IIa trial of VTD-panobinostat treatment and panobinostat maintenance in relapsed and relapsed/refractory multiple myeloma patients

niversity of Leeds (UK)0 个研究点目标入组 54 人开始时间: 2012年12月19日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
54
研究概览入排标准研究者记录与标识符相似试验

研究概览

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •1. Patients with a previous diagnosis of multiple myeloma based on IMWG 2003 definitions:
  • •1.1. Monoclonal immunoglobulin (M component) on electrophoresis, and on immunofixation of serum or of total 24 hour urine
  • •1.2. Bone marrow (clonal) plasma cells =10% or biopsy proven plasmacytoma
  • •1.3. Related organ or tissue impairment (CRAB symptoms, anemia, hypercalcemia, lytic bone lesions, renal insufficiency, hyperviscosity, amyloidosis or recurrent infections)
  • •2. Relapsed or relapsed-and-refractory myeloma who have received 14 prior lines and now require further treatment
  • •3. Able to give informed consent and willing to follow study protocol
  • •4. Aged 18 years or over
  • •5. ECOG Performance Status = 2
  • •6. Required laboratory values within 14 days of registration:
  • •6.1. Absolute neutrophil count = 1.0 x 109/L. Growth factor support is not permitted within 14 days prior to eligibility assessment
  • •6.2. Platelet count = 100 x 109/L. Platelet support is not permitted within 14 days prior to eligibility assessment
  • •6.3. Haemoglobin = 8.0g/dL. Blood transfusion support is permitted
  • •6.4. Bilirubin = 2 x upper limit of normal (ULN)
  • •6.5. AST and/or ALT = 2.5 x ULN; except in subjects with known hepatic involvement, where AST and/or ALT = 5.0 x ULN
  • •6.6. Serum creatinine = 2.0 x ULN
  • •6.7. Corrected calcium = 2.8 mmol/L
  • •7. Anticipated survival of at least 3 months
  • •8. Evaluable disease per modified IWG criteria, utilising the following assessments as appropriate:
  • •8.1. Serum M protein = 10g/l
  • •8.2. Urine M protein = 200mg/24 hours
  • •8.3. Serum free light chain assay: involved FLC level = 100mg/l. Provided serum FLC ratio is abnormal
  • •9. Female subjects of childbearing potential must have a negative pregnancy test at baseline and agree to use dual methods of contraception for the duration of the study and must continue to do so for 3 months after the end of treatment. Male subjects must agree to use a barrier method of contraception for the duration of the study if sexually active with a female of childbearing potential and must continue to do so for 3 months after the end of treatment.
  • •10. Male or female participants

排除标准

  • •1. Pregnant (positive pregnancy test) or breastfeeding women
  • •2. Non-secretory multiple myeloma
  • •3. Previous anti-tumour therapies, including prior experimental agents or approved anti-tumour small molecules and biologics, within 28 days before the start of protocol treatment. Steroid therapy is permitted (maximum 160mg dexamethasone or equivalent), but must be stopped 48 hours prior to study drug administration. Bisphosphonates for bone disease and radiotherapy for palliative intent are also permitted.
  • •4. Concurrent or previous malignancies (<12 months post end of treatment) at other sites with the exception of appropriately treated localised epithelial skin or cervical cancer, or incidental histologic findings of prostate cancer (TMN stage T1a or 1b). Patients with histories (=12 months) of other tumours may be entered
  • •5. Poorly controlled or serious medical or psychiatric illness that, in the Investigator?s opinion, is likely to interfere with participation and/or compliance in this clinical study
  • •6. Patients with significant cardiovascular disease (e.g. history of congestive heart failure requiring therapy, presence of severe valvular heart disease, presence of an atrial or ventricular arrhythmia requiring treatment, uncontrolled hypertension, a history of QTc abnormalities)
  • •7. Active symptomatic fungal, bacterial, and/or viral infection including known active HIV or known viral (A, B, or C) hepatitis
  • •8. Gastrointestinal disorders that may interfere with absorption of the study drug
  • •9. Patients who have been refractory to prior bortezomib, i.e. did not achieve at least an MR, or who have progressed on therapy or within 60 days of last dose
  • •10. Participants with peripheral neuropathy CTC grade 2 or higher or grade 1 with pain within 14 days prior to registration
  • •11. Any history of known hypersensitivity to any of the study medication or excipients

研究者

发起方
niversity of Leeds (UK)

相似试验

进行中（未招募）
1 期
The use of Panobinostat, administered in combination with Velcade, Thalidomise and Dexamethasone, in subjects with relapsed and relapsed/refractory multiple myeloma.
EUCTR2012-000842-36-GBniversity of Leeds57
Unknown
1 期
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple MyelomaMultiple Myeloma
NCT02145715Prof Jamie Cavenagh54
终止
1 期
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After TrastuzumabBreast Cancer
NCT00567879Novartis Pharmaceuticals56
已完成
2 期
A phase II study of vinblastine, endoxana (cyclophosphamide), procarbazine, prednisolone, etoposide, mitoxantrone and bleomycin in patients with Hodgkin's lymphoma aged over 60 yearsHodgkin's lymphomaCancer
ISRCTN87375595ewcastle Hospitals NHS Trust (UK)150
已完成
2 期
Vorinostat in combination with bortezomib and dexamethasone in patients with relapsed and relapsed refractory multiple myelomaRelapsed or relapsed and refractory multiple myelomaCancerMultiple myeloma
ISRCTN08577602niversity of Leeds (UK)16
MUK six | 临床试验